Journal of Clinical Epigenetics
ISSN: 2472-1158

Open access Opinion

Imprinting Epigenetics and Personalized Medicine New Frontier in Treatment

Kelley Williams*

Department of Epigenetics, Carnegie Mellon University, United States

INTRODUCTION

Imprinting epigenetics refers to a phenomenon where genes are expressed in a parent-of-origin-specific manner. This means that the expression of a particular gene depends on whether it was inherited from the mother or the father. Imprinting plays a crucial role in development and has been linked to various diseases and syndromes. This article will explore the mechanisms, significance, disorders associated with imprinting, and the potential therapeutic applications. Imprinting is a complex process that involves several epigenetic modifications, including DNA methylation and histone modification. These modifications can either activate or silence specific genes, depending on the parent from whom they were inherited. DNA at specific regions, known as imprinting control regions (ICRs), can silence genes. This methylation pattern is established in the germ cells and maintained throughout development.

DESCRIPTION

Histone Modifications and Changes to the histone proteins around which DNA is wound can also regulate imprinted gene expression. Non-Coding RNAs Some imprinted genes produce non-coding RNAs that play a role in regulating other genes within the imprinted region. Imprinting is essential for normal development, particularly in the placenta and brain. It ensures that specific genes are expressed at the right levels and at the right times, depending on whether they are maternally or paternally inherited. The parental conflict theory suggests that imprinting evolved as a result of conflicting interests between maternal and paternal genes. For example, paternal genes may promote growth to ensure the offspring's survival, while maternal genes may limit growth to conserve resources for future offspring. Imprinting disorders occur when the normal pattern of imprinting is disrupted. These disorders can result from deletions, mutations, or other changes in the ICRs. Prader-Willi Syndrome PWS is caused by the loss of function of paternally expressed genes in a specific region of chromosome 15. Symptoms include intellectual disability, obesity, and behavioral problems. Angelman Syndrome (AS) results from the loss of function of a maternally expressed gene in the same region as PWS. It leads to developmental delays, seizures, and a characteristic happy demeanor. Beckwith-Wiedemann Syndrome (BWS) is associated with abnormalities in imprinted genes on chromosome 11, leading to overgrowth and an increased risk of tumors. Understanding imprinting mechanisms offers potential therapeutic avenues, particularly in cancer, where imprinted genes are often dysregulated. Targeting Imprinted Genes in Cancer some imprinted genes act as tumor suppressors or oncogenes.

CONCLUSION

Targeting these genes with epigenetic therapies may provide new treatment options. Diagnostic and Prognostic Markers Imprinted genes may serve as biomarkers for diagnosing or predicting the course of various diseases. Imprinting epigenetics adds a fascinating layer of complexity to genetic regulation. It plays a vital role in development and has been linked to a range of disorders, from developmental syndromes to cancer. The mechanisms of imprinting, involving DNA methylation, histone modifications, and non-coding RNAs, are intricate and still not fully understood. The study of imprinting offers insights into fundamental biological processes and the evolutionary forces shaping them. It also opens doors to potential therapeutic applications, particularly in the context of personalized medicine. As research in this field continues to advance, the mysteries of imprinting are gradually being unraveled, shedding light on a remarkable aspect of our genetic heritage and offering new possibilities for understanding and treating human diseases.

Received:	03-July-2023	**Manuscript No:**	ipce-23-17560
Editor assigned:	05-July-2023	**PreQC No:**	ipce-23-17560 (PQ)
Reviewed:	19-July-2023	**QC No:**	ipce-23-17560
Revised:	24-July-2023	**Manuscript No:**	ipce-23-17560 (R)
Published:	31-July-2023	**DOI:**	10.21767/2472-1158-23.9.66

Corresponding author Kelley Williams, Department of Epigenetics, Carnegie Mellon University, United States, E-mail: kelleywilliams@epigenetics.edu

Citation Williams K (2023) Imprinting Epigenetics and Personalized Medicine New Frontier in Treatment. J Clin Epigen. 9:66.